The shortlist categories are divided into FOUR groups:
Has your company won an Excellence Award?
Search to find out if your company is a winner
Excellence Categories – These categories look at achievements in our core areas of excellence and include everything from Covid-19 Response to Social Impact.
Sector Excellence – These categories look at achievements within each individual market sub-sector and can include everything from notable business expansion through innovation to diversity and environmental initiatives.
Firms of the Year – These categories look at achievements by specific types of companies and includes everything from new market entrants to finance and legal firms.
Deals of the Year – The most notable finance and M&A deals from the research period.
*Please note that we also have awards for individuals, the winners of which will be announced in our Awards Report alongside the other category winners
Excellence Categories
BUSINESS EXPANSION
- Ajinomoto Bio-Pharma
- Arcus Biosciences, WuXi Biologics
- Dot Compliance
- Eli Lilly, Biologics
- Excellims
- GlaxoSmithKline (GSK)
- Nexus
- Regeneron
- Samsung Biologics
- Takeda
- UCB, Microsoft
COVID-19 RESPONSE
- Altimmune, DynPort
- Bharat Biotech, Ocugen
- Curevac
- Destiny Pharma, SporeGen
- Dynavax, Medigen
- GlaxoSmithKline (GSK)
- Intravacc, Celonic
- Medicago
- Moderna
- Novartis, Molecular Partners
- Oramed
- Roche, Regeneron
- SK, Novavax
- Symvivo
- Takeda
- T-scan
ENVIRONMENTAL IMPACT
- Alliance to Zero
- Lloyd
- The Sustainable Healthcare Coalition
INNOVATION
- Exscientia, BMS
- GlaxoSmithKline (GSK)
- NVIDIA
- Piezo Motion
- University of California, San Diego
- University of California, Berkeley
PRODUCT LAUNCH
RESEARCH AND DEVELOPMENT
- Adagio Therapeutics
- Ampio
- BioMarin, Deep Genomics
- Codiak, Sarepta
- CRUK, Teon
- Oxford University
- Pfizer, BioNTech
- Scancell
SAFETY
- ArisGlobal
- TransPerfect
SOCIAL IMPACT
- The Altrui Foundation
- Galt Pharmaceuticals
- NGM Biopharmaceuticals
- Oximio
Sector Excellence
CARDIOVASCULAR
- Abbott
- AstraZeneca
- Humacyte
CENTRAL NERVOUS SYSTEM
- AbbVie, Caraway
- Biogen, Denali
- Eli Lilly, Verge Genomics
- Exscientia, Blue Oak
- GlaxoSmithKline (GSK), Alector
- Ipsen, Exicure
- Janssen
- PTC Therapeutics
- Roche, UCB
CLINICAL TRIALS
- AbbVie, Calico
- Cytodyn, Biomm
- Gilead, Novo Nordisk
- Hoth Therapeutics, UCRI
- Moderna
- Novavax
- Pfizer, BioNTech
DRUG DEVELOPMENT
- Arcus Biosciences, WuXi Biologics
- Arrowhead, Horizon
- BioMarin
- FUJIFILM Cellular Dynamics
- GI Innovation
- insitro
- IQVIA
- Merck
- Roivant Sciences
- UCB, Microsoft
- Viking Therapeutics
IMMUNOLOGY
- Amgen, Kyowa Kirin
- Biogen, В Bio-Thera
- Lilly, Rigel
INFECTIOUS DISEASES
- Exscientia
- Gilead Sciences
- Halozyme, ViiV Healthcare
- Takeda, Frazier
- Vaxart, Altesa
MANUFACTURING
- Amgen
- BioNTech, Novartis
- Cellares, Poseida Therapeutics
- Eisai, Seikagaku
- Irisys
- Moderna, Lonza
- Regeneron
- Samsung Biologics
- Sandoz
- Takeda
- Thermo Fisher Scientific
- VIVEbiotech
- WuXi AppTec, OXGENE
ONCOLOGY
- AbbVie, I-Mab
- Arcus Biosciences, WuXi Biologics
- AstraZeneca, Daiichi Sankyo
- Bayer, Triumvira Immunologics
- Bristol-Myers Squibb (BMS), Agenus
- Boehringer, Enara Bio
- Byondis, Glycotope
- CRUK, Teon
- Eisai, BMS
- Gilead, Tango Therapeutics
- HiFiBiO
- Revitope Oncology
- Pfizer
- Rhizen, Curon
- Twist, Neogene
- Umoja Biopharma
RESPIRATORY
- Icosavax
- Moderna
- Partner Therapeutics
- Pieris, Genentech
- Verona
SUPPLY CHAIN
- CalAmp
- Merck, BioNTech
- USP
Firm of the Year
DISRUPTOR
- Beam Therapeutics
- BeiGene
- Blueprint Medicines
- ClouDr
- Exscientia
- Five Prime Therapeutics
- GI Innovation
- Insitro
- Nvidia
- Zymergen
FINANCE
- Bank of America
- Barclays
- Centerview Partners
- Citigroup
- Cowen
- Evercore
- Guggenheim Partners
- JPMorgan Chase & Co/J.P. Morgan Securities
- Jefferies
- Lazard
- Morgan Stanley
- The Goldman Sachs Group
LEGAL
- Allen & Overy
- Cooley
- Cravath, Swaine & Moore
- Davis Polk & Wardwell
- Freshfields Bruckhaus Deringer
- Fried, Frank, Harris, Shriver & Jacobson
- Goodwin Procter
- Kirkland & Ellis
- Latham & Watkins
- Ropes & Gray
- Simpson Thacher & Bartlett
- Wachtell, Lipton, Rosen & Katz
NEWCOMER
- Alphazyme
- Beam Therapeutics
- Insitro
- Recursion Pharmaceuticals
- Relay Therapeutics
PRIVATE EQUITY/VC
- Bain Capital
- BC Partners
- EQT Partners
- Hellman & Friedman
- Pamplona Capital Management
- Partners Group
- Permira
- The Blackstone Group
- The Carlyle Group
SME
- Beam Therapeutics
- Five Prime Therapeutics
- GI Innovation
- Insitro
- Revitope Oncology
- Unchained Labs
- Viking Therapeutics
Deal of the Year
FINANCE
- Biomat
- Everest Med
- Hepalink
- Legend Bio
- Relay Tx
- Remegen
- Simcere
- Sotera Health
M&A (impact)
- AstraZeneca acquires Alexion
- Danaher acquires Aldevron
- Gilead Sciences acquires Immunomedics
- Horizon acquires Viela Bio
- Eli Lilly acquires Prevail Therapeutics
- Merck & Co. acquires VelosBio
- Nestlé acquires Aimmune Therapeutics
- PerkinElmer acquires BioLegend
- Thermo Fisher Scientific acquires PPD
